+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Bispecific Antibodies for Cancer Market 2019-2023- Product Image
Global Bispecific Antibodies for Cancer Market 2019-2023- Product Image

Global Bispecific Antibodies for Cancer Market 2019-2023

  • ID: 4769228
  • Report
  • April 2019
  • Region: Global
  • 117 pages
  • TechNavio

FEATURED COMPANIES

  • Amgen Inc.
  • Astella Pharma Inc.
  • Merus
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. The analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Market Overview

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view this report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Astella Pharma Inc.
  • Merus
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET
  • Market segmentation by target
  • Comparison by target
  • CD19/CD3 - Market size and forecast 2018-2023
  • CD30/CD16A - Market size and forecast 2018-2023
  • Market opportunity by target
PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
  • Merus
  • Regeneron Pharmaceuticals, Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Bispecific antibodies for cancer under development
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Customer landscape
Exhibit 19: Target - Market share 2018-2023 (%)
Exhibit 20: Comparison by target
Exhibit 21: CD19/CD3 - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: CD19/CD3 - Year-over-year growth 2019-2023 (%)
Exhibit 23: CD30/CD16A - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: CD30/CD16A - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by target
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Pipeline for bispecific antibodies for cancer treatment
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Amgen Inc. - Vendor overview
Exhibit 46: Amgen Inc. - Product segments
Exhibit 47: Amgen Inc. - Organizational developments
Exhibit 48: Amgen Inc. - Geographic focus
Exhibit 49: Amgen Inc. - Key offerings
Exhibit 50: Astella Pharma Inc. - Vendor overview
Exhibit 51: Astella Pharma Inc. - Business segments
Exhibit 52: Astella Pharma Inc. - Organizational developments
Exhibit 53: Astella Pharma Inc. - Key offerings
Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Vendor overview
Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. - Key offerings
Exhibit 56: Merus - Vendor overview
Exhibit 57: Merus - Product segments
Exhibit 58: Merus - Key offerings
Exhibit 59: Regeneron Pharmaceuticals, Inc. - Vendor overview
Exhibit 60: Regeneron Pharmaceuticals, Inc. - Business segments
Exhibit 61: Regeneron Pharmaceuticals, Inc. - Organizational developments
Exhibit 62: Regeneron Pharmaceuticals, Inc. - Key offerings
Exhibit 63: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Astella Pharma Inc.
  • Merus
Global Bispecific Antibodies for Cancer Market 2019-2023

The analyst recognizes the following companies as the key players in the global bispecific antibodies for cancer market: Amgen Inc., Astella Pharma Inc., Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd., Merus, and Regeneron Pharmaceuticals, Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emerging bispecific antibody generation platforms.”

According to the report, one of the major drivers for this market is the advantages of bispecific antibodies over monoclonal antibodies.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of BLINCYTO.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Astella Pharma Inc.
  • Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.
  • Merus
  • Regeneron Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll